BOEHRINGER INGELHEIM ENTERS GLOBAL LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE INNOVATIVE ANTIBODIES FROM A*STAR FOR TARGETED CANCER THERAPIES
2.6.2022 16:10:00 EEST | Business Wire | Press release
Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR. Boehringer Ingelheim aims to use these antibodies to direct therapeutic effector mechanisms such as antibody-drug conjugates (ADCs) and T-cell engagers exclusively to tumor cells, and to that end develop a range of highly targeted cancer treatments.
“Boehringer Ingelheim believes that these promising antibodies in-licensed from A*STAR will help us advance potent therapeutic candidates against key molecular cancer targets,” says Clive R. Wood, Senior Corporate Vice President and Global Head of Discovery Research at Boehringer Ingelheim and continues: “We look forward to developing these assets for a broad range of cancers with the goal to deliver breakthrough opportunities for patients.”
Boehringer Ingelheim is pioneering a range of versatile therapeutic platforms in order to develop innovative medicines that target the tumor directly (tumor cell-directed therapies) or that enable the immune system to target the tumor (immune cell-targeted therapies). One tumor cell-directed modality is antibody drug conjugates, which allows for delivery of toxins directly into tumor cells. Another is T-cell engagers facilitating direct contact between T-cells and tumor cells, leading to T-cell-mediated killing of the tumor. Both technologies are directed towards markers on the surface of cancer cells, also known as antigens, in order to attack tumor cells but spare healthy tissues.
The innovative antibodies from A*STAR can potentially enable the development of safer, more efficacious therapies as they selectively bind to antigens that are highly expressed on tumor cells but are absent on normal healthy tissues.
Under the terms of the agreement, Boehringer Ingelheim will be responsible for further research, preclinical and clinical development as well as commercialization of targeted cancer therapies using the antibodies from A*STAR. A*STAR may receive payments totalling >100 million EUR in upfront and success-based development and commercialization milestones.
The technology used to identify the unique A*STAR antibodies resulted from a multi-institutional collaboration in Singapore. A*STAR’s Genome Institute of Singapore (GIS) and Institute of Bioengineering & Bioimaging (IBB) generated antibodies which exclusively target antigens that were initially identified from gastric cancer cells. Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development hosted by A*STAR, then optimized the antibodies and confirmed their applicability to a range of other solid cancers. EDDC also demonstrated the utility of these antibodies in directing different therapeutic modalities selectively to cancer cells.
Professor Damian O'Connell, Chief Executive Officer of EDDC, says, “As Singapore's national drug discovery and development platform, EDDC is proud to translate great science in Singapore into valuable assets that can enable the precise treatment of cancer. We believe that Boehringer Ingelheim, with its broad expertise and technologies, is the right partner to maximize the potential of these antibodies for the development of safer, more targeted therapies for cancer patients.”
Professor Tan Sze Wee, Assistant Chief Executive (Enterprise) of A*STAR, says, “These antibodies were developed in Singapore through close collaboration across multiple institutions. There was also strong support by the Singapore Gastric Cancer Consortium. The agreement is testament to the best-in-class research taking place in Singapore. Cancer is a devastating disease, and we hope the fruits of our research can improve patient outcomes.”
Please click on the link for “Note to Editors’ and ‘References’:
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005475/en/
Contact information
For media queries and clarifications:
Dr. Reinhard Malin
Innovation Unit Communications
Corporate Affairs
Boehringer Ingelheim
Tel: +49 6132 77-90815
Email: reinhard.malin@boehringeringelheim.com
Owen Sia
Assistant Head, Corporate Communications
Agency for Science, Technology and Research
Tel: +65 6517 7866
Email: owen_sia@hq.a-star.edu.sg
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
72% of Organizations Have Delayed, Scaled Back or Paused AI and Edge Projects Over Resilience Concerns18.11.2026 10:01:00 EET | Press release
Nearly three in four organizations (72%) have delayed, scaled back or paused an AI or edge project in the past 12 months over concerns about network resilience, according to new research from Opengear, a Digi International company (NASDAQ: DGII) (www.digi.com). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118888190/en/ 72% of Organizations Have Delayed, Scaled Back or Paused AI and Edge Projects Over Resilience Concerns The same research shows how the best-prepared organizations fare. Organizations with embedded network resilience, meaning they can reach and recover critical infrastructure when the primary network is down, reported estimated average outage costs $6 million lower over the past 12 months than organizations with less developed resilience capabilities ($12.4 million versus $18.8 million). The advantage extends beyond outages to deployment, routine operations, and incident readiness. Concern reaches organiza
SWISSto12 Selects DLR GSOC as Flight Dynamics Software Partner to Support Upcoming HummingSat Satellite Missions18.11.2026 10:00:00 EET | Press release
SWISSto12, one of the world’s fastest-growing satellite and aerospace companies, today announced it has contracted the German Aerospace Center (DLR) to serve as the company’s primary flight dynamics software provider across its upcoming HummingSat GEO satellite missions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118073472/en/ SWISSto12 has selected DLR’s GSOC as its primary flight dynamics software provider for upcoming HummingSat GEO satellite missions. Under this agreement, GSOC will deliver capabilities that span orbit determination, propagation, manoeuvre planning and calibration, orbit events, antenna pointing, and long-term mission analysis. The collaboration is designed to standardise flight dynamics across SWISSto12 programmes, using a heritage European solution integrated into the company’s ground segment architecture. GSOC is part of the DLR Space Operations and Astronaut Training institution in Oberpfaffen
Abbove Brings European Wealth Planning Into the AI Era18.11.2026 09:05:00 EET | Press release
Abbove, the European wealth planning platform used by more than 1,450 advisors serving more than 40,000 families across Europe, today launched its MCP connector. Through the open Model Context Protocol, advisors can put their clients’ complete wealth picture to work in the AI tools their institution has chosen, such as Claude, ChatGPT, Mistral or Copilot, within their access rights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117076275/en/ One question, your whole client book: your AI tool reads Abbove and shows which clients have cash coming free in the next 12 months, with dates and amounts. The difference lies in the data.AI tools are only as good as the data they consume. Abbove builds on its ability to model each family’s wealth data in a complete and structured way. Co-built by advisors and their client families, it captures what aggregation alone cannot: goals, life events, gifts, the full picture of the family
Wolters Kluwer’s Future Ready Accountant report: Redesigning work around AI is the next competitive advantage18.11.2026 07:00:00 EET | Press release
Wolters Kluwer Tax & Accounting today released the third edition of its Future Ready Accountant report, revealing a profession operating from a position of strength but at a turning point. Based on responses from more than 2,600 accounting professionals worldwide, the report finds firms are growing, confident, and widely adopting AI. However, few have redesigned how information, workflows, and professional expertise work together. The report shows that this transformation is what will turn today’s growth into lasting value. “Adopting AI is only the first step. The real advantage comes from connecting it to how the whole firm works,” said Jason Marx, CEO, Wolters Kluwer Tax & Accounting. “This year’s Future Ready Accountant report shows the firms that pull ahead will be the ones that rethink their workflows and give their people more room to create value for clients.” The global report features exclusive editions for the U.S., Canada, Europe, and APAC markets, offering region-specific i
Visa Expands Agentic Ready to Help Scale Trusted AI Commerce Globally18.11.2026 06:30:00 EET | Press release
Visa (NYSE: V), a world leader in digital payments, today announced the expansion of the Visa Agentic Ready program to the acceptance ecosystem. As a part of Visa Intelligent Commerce, the expanded program helps merchants, payment service providers (PSPs), and acquirers prepare for agent-initiated transactions and participate in the next era of commerce. The program is launching with more than 140 participants, with additional financial institutions, merchants and enablers expected to join throughout 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117269823/en/ "Agentic commerce is already taking shape, but scaling it requires more than innovation. Merchants need confidence in who they're transacting with, and payment providers need to know these transactions can move securely and reliably through existing infrastructure," said Rubail Birwadker, SVP, Growth Products & Partnerships, Visa. "No one company can solve tha
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
